Methods and compositions for delivering active agents with enhanced pharmacological properties

Abstract

Provided herein are methods of enhancing in vivo efficacy of an active agent, comprising: administering to a subject an active agent that is coupled to a bioelastic polymer or elastin-like peptide, wherein the in vivo efficacy of the active agent is enhanced as compared to the same active agent when administered to the subject not coupled to (or not associated with) a bioelastic polymer or ELP.

Description

PRIORITY[0001]This application is a continuation-in-part of U.S. patent application Ser. No. 13 / 674,285, filed Nov. 12, 2012, which is a continuation of Ser. No. 12 / 158,190, filed Sep. 2, 2008 (now U.S. Pat. No. 8,334,257), which is a national phase application of PCT Application No. PCT / US2006 / 048572, filed Dec. 20, 2006, and published in English on Jun. 28, 2007, as International Publication No. WO 2007 / 073486, and which claims the benefit of U.S. Provisional Patent Application Ser. No. 60 / 751,896, filed Dec. 20, 2005, the disclosure of each of which is incorporated by reference herein in its entirety.GOVERNMENT FUNDING[0002]This invention was made with Government support under grant number EB00188 and GM-061232 from the National Institutes of Health. The US Government has certain rights to this invention.DESCRIPTION OF THE TEXT FILE SUBMITTED ELECTRONICALLY[0003]The contents of the text file submitted electronically herewith are incorporated herein by reference in their entirety:...

AI Technical Summary

Benefits of technology

[0009]The present invention provides a method of enhancing in vivo efficacy of an active agent, comprising: administering to a subject an active agent that is coupled to a bioelastic polymer or elastin-like peptide, wherein the in vivo efficacy of the active agent is enhanced as compared to the same active agent when administered to the subject not coupled to (or not associated with) a bioelastic polymer or ELP. In vivo efficacy may be enhanced in one, or more, of the following ways: solubility, bioavailability, effective therapeutic dose, formulation compatibility, resistance to proteolysis, half-life of the administered peptide active therapeutic agent, persistence in the body subsequent to administration, and rate of clearance from the body subsequent to administration.

Problems solved by technology

A significant problem with many candidate drugs, or even drugs in clinical use, is insufficient or unsatisfactory in vivo efficacy.

Insufficient in vivo efficacy can be manifested in a variety of ways, such as (i) low bioavailability of the active compound; (ii) undesirably short half-life of the active compound, (iii) and / or undesirably high systemic toxicity of the active compound.

Images